SINOMED(SH:688108) Cai Jing Wang·2025-09-04 10:58Core Insights - The management of the company highlighted the high domestic replacement rate of coronary intervention products in China, while noting that neurointervention is in an early rapid development stage with increasing domestic replacement rates [1] - The company is focused on the application of new materials and advanced technologies in key interventional areas, indicating a significant demand for innovative solutions to clinical pain points in vascular intervention [1] - The company plans to concentrate on mitral valve replacement in the structural heart disease intervention field and will focus on evidence-based medical research to demonstrate the superiority of interventional treatment methods over current drug therapies for cerebral vascular stenosis [1] - The company is closely monitoring the development of new technologies, including brain-computer interfaces, and seeks to provide solutions based on its vascular intervention technology, IT, and professional advantages [1] - As of the date of the half-year report, the company has obtained 73 overseas registration certificates for its coronary products and is actively expanding its overseas coronary business [1]